BioModifying Inc. is a pioneering, clinical-stage biopharmaceutical organization dedicated to transforming disease intervention. By developing advanced biomodulatory therapeutics, gene correction systems, and synthetic cellular platforms, we aim to intercept pathological processes at their core molecular origin.
🔬 Our Core Scientific Platforms
In Vivo Gene Editing (CRISPR-Cas24)
Our custom CRISPR systems use high-fidelity, dual-cleavage enzymes to selectively silence or correct mutations in hepatocytes and hematopoietic tissues. By utilizing tissue-specific lipid nanoparticles (LNPs), we achieve targeted delivery with minimal off-target activity.
mRNA Transcription Modulation
We design synthetic mRNA molecules optimized for high translation efficiency and low immunogenic profiles. These transcripts instruct patient cells to produce therapeutic enzymes, cytokines, or neutralizing antibodies directly within target organs.
CAR-NK Solid Tumor Interception
By engineering natural killer (NK) cells derived from cord blood with chimeric antigen receptors (CAR), we have developed "off-the-shelf" cellular therapies capable of penetrating and destroying vascularized glioblastomas and sarcomas.
📈 Clinical Development Pipeline
Our investigational therapeutic assets target severe, underserved indications in oncology, immunology, and metabolic genetics.
| Asset ID | Target Indication | Platform / Mechanism | Current Status |
|---|---|---|---|
| BM-102 | Glioblastoma Multiforme | CAR-NK Cellular Therapy | Phase Ib Clinical Trials |
| BM-205 | Transthyretin Amyloidosis | In Vivo CRISPR Silencing (LNP) | Pre-clinical Testing |
| BM-312 | Refractory Rheumatoid Arthritis | Anti-inflammatory mRNA Vector | Phase IIa Clinical Trials |
| BM-408 | Hereditary Angioedema | mRNA Transcript Translation | IND-Enabling Phase |